Targeted therapy for metastatic renal cell carcinoma

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:umu-176044" > Targeted therapy fo...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Hofmann, FabianUmeå universitet,Urologi och andrologi (author)

Targeted therapy for metastatic renal cell carcinoma

Article/chapterEnglish2020

Publisher, publication year, extent ...

John Wiley & Sons,2020
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:umu-176044
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-176044URI
https://doi.org/10.1002/14651858.CD012796.pub2DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:for swepub-publicationtype

Notes

Related publication: Hofmann F., Marconi L.S.O., Stewart F., Lam T.B.L., Bex A., Canfield S.E., Ljungberg B. Targeted therapy for metastatic renal cell carcinoma [Protocol - Intervention]. Cochrane Database of Systematic Reviews 2017, (9): CD012796. DOI:10.1002/14651858.CD012796
Background: Several comparative randomised controlled trials (RCTs) have been performed including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors since the publication of a Cochrane Review on targeted therapy for metastatic renal cell carcinoma (mRCC) in 2008. This review represents an update of that original review.Objectives: To assess the effects of targeted therapies for clear cell mRCC in patients naïve to systemic therapy.Search methods: We performed a comprehensive search with no restrictions on language or publication status. The date of the latest search was 18 June 2020.Selection criteria: We included randomised controlled trials, recruiting patients with clear cell mRCC naïve to previous systemic treatment. The index intervention was any TKI‐based targeted therapy.Data collection and analysis: Two review authors independently assessed the included studies and extracted data for the primary outcomes: progression‐free survival (PFS), overall survival (OS) and serious adverse events (SAEs); and the secondary outcomes: health‐related quality of life (QoL), response rate and minor adverse events (AEs). We performed statistical analyses using a random‐effects model and rated the certainty of evidence according to the GRADE approach.Main results: We included 18 RCTs reporting on 11,590 participants randomised across 18 comparisons. This abstract focuses on the primary outcomes of select comparisons.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

Chang Hwang, E. (author)
Lam, Thomas B.L. (author)
Bex, Axel (author)
Yuan, Yuhong (author)
Marconi, Lorenzo S.O. (author)
Ljungberg, Börje,Professor,1949-Umeå universitet,Urologi och andrologi(Swepub:umu)bolj0001 (author)
Umeå universitetUrologi och andrologi (creator_code:org_t)

Related titles

In:Cochrane Database of Systematic Reviews: John Wiley & Sons:101469-493X

Internet link

Find in a library

Cochrane Database of Systematic Reviews (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Hofmann, Fabian; Chang Hwang, E.; Lam, Thomas B.L.; Bex, Axel; Yuan, Yuhong; Marconi, Lorenzo ...; show more...; Ljungberg, Börje ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Urology and Neph ...

Articles in the publication: Cochrane Databas ...

By the university: Umeå University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se